Pharmafile Logo

Spotlight on Saudi Arabia

August 25, 2015 | Saudi Arabia, emerging markets 

Published in eyeforpharma 20 May by Rachel Howard

What are the opportunities and challenges for pharma companies wishing to gain a foothold in this oil-rich kingdom?

Traditionally the Middle East and North Africa (MENA) region has been overlooked by pharmaceutical companies, with the region contributing only about 2% of global pharmaceutical sales in 2010. Difficult regulatory environments and political turmoil have compounded the perceived lack of attractiveness of the region as a whole.

As we reach the middle of the decade, could the tide be turning? Over the last year, I have noticed increasing industry interest in Saudi Arabia (KSA) – and with good reason given it is the fastest growing pharmaceutical market in the Middle East, experiencing double-digit growth. In this article, I will take a look at the opportunities and challenges for pharma companies wishing to gain a foothold in this oil-rich kingdom.

Background

Though vast swathes of the country are uninhabitable desert, Saudi Arabia has a population fast approaching 30 million. It is a young country, with over half of the population under 30 years of age. As it is home to the holy Islamic cities of Mecca and Medina, its population receives a seasonal boost as over two million pilgrims visit each year to perform the Hajj. It also contains about a quarter of the world’s known petroleum reserves, and oil revenues account for approximately 90 percent of the government’s income.

A key pillar of Saudi Arabia’s internal stability relative to much of the surrounding region has been the kingdom’s generous social welfare system, of which healthcare forms an important segment. Healthcare services are available free of charge not only to Saudi citizens but also to all pilgrims, regardless of their nationality. Recent decades have seen considerable improvement in both the quantity and quality of healthcare services. A Royal Decree in 2002 resulted in sizeable expansion of the primary care network. Care in the top public hospitals, such as Riyadh’s renowned King Fahad Medical City, easily rivals that of the West, with imported medical technology and state-of-the-art facilities. Medical education is also fully funded by the state, including overseas training. As a result, many physicians are trained in leading US and UK medical schools.

However, not all is rosy. Despite the country’s affluence and stated commitment to healthcare, indicators suggest Saudi Arabia’s overall healthcare performance remains mediocre compared with the West, with an infant mortality rate that is double the average and a shorter life expectancy.

Read the full article at http://www.researchpartnership.com/news/2015/05/spotlight-on-saudi-arabia/

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Webcast: Poker face revealed: Using facial analysis to uncover deeper levels of emotional insight

In the first part of our series covering market research innovations which have value in healthcare, we demonstrate how we've been using facial analysis to delve further into respondents' reactions...

Report: Living with RA (EU, Japan and Canada) 2019 reports

Research Partnership launches new patient Living with  Rheumatoid Arthritis (EU & Japan)  2019 report.r Living with Rheumatoid Arthritis (RA) is a quantitative study conducted online amongst 390 patients diagnosed with RA in...

News: Therapy Watch launches a new wave of EU tracking in Psoriasis (PsO)

A panel of 40 dermatologists in each of the major EU markets reports on patients on advanced therapies including biologics and small molecule therapies every quarter. In addition from Q1...

Emerging Markets: Your Essential Guide

Using our combined knowledge and years of experience of working in these territories our emerging markets experts have produced this essential guide to help address some of the core challenges...

Live webinar: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorumThursday 21st March 201915:00 GMT / 16:00 CETRegister now to secure your place »The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors,...

New appointments in our UK and New York offices

Research Partnership is delighted to announce various appointments across our offices. Ella Buckland joins as Research Executive, Ines Belchior joins as Research Analyst, and Emma Warburton joins as Business Development...

Pharma Market Research Conference NJ, 2019

We are delighted to be presenting and exhibiting at PMRC, 6-7 February in Newark, NJ.Representing Research Partnership at the conference will be New York-based Directors Liza Pliss and Mariana Servin.Liza...

Research Partnership ranks 13th in the top 20 fastest-growing agencies in the UK

The UK’s best performing market research agencies were revealed earlier this month with the publication of Research Live’s Industry Report for 2019, which includes the latest Market Research Society (MRS)...

Vaccines: Our experience and expertise

We have designed a complimentary infographic outlining the market opportunity as well as our experience and expertise in the area of vaccines. The infographic also includes links to a range of...

Conference Live: Case study

How we helped track and evaluate conference performance over time across multiple international events